Change in Quality of Life for Patients with Irritable Bowel Syndrome following Referral to a Gastroenterologist: A Cohort Study

被引:24
作者
Canavan, Caroline [1 ]
West, Joe [1 ]
Card, Timothy [1 ]
机构
[1] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England
来源
PLOS ONE | 2015年 / 10卷 / 10期
基金
英国医学研究理事会;
关键词
WORK PRODUCTIVITY; PRIMARY-CARE; RISK-FACTORS; PREVALENCE; COLONOSCOPY; SYMPTOMS; IMPACT; IMPAIRMENT; COSTS;
D O I
10.1371/journal.pone.0139389
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Irritable bowel syndrome (IBS), a chronic functional condition, considerably reduces quality of life (QoL) and referral to gastroenterology is common. Until now, however, the impact of seeing a gastroenterologist for IBS on patients' QoL and utility has not been assessed. Methods Patients referred with "probable IBS" to the Nottingham Treatment Centre between October 2012 and March 2014 were invited to complete a QoL questionnaire (EuroQol-5 Dimension) before their first appointment. Patients with confirmed IBS who completed this baseline assessment were sent follow-up questionnaires three and twelve months later. Global QoL and utility were measured at each time point and change from baseline calculated. Paired t-tests analysed the significance of any change. Results Of 205 invited patients, 69 were eligible and recruited. Response at three and twelve months was 45% and 17% respectively. Median global QoL at baseline was 67.5 (Interquartile range [IQR] 50.0 to 80.0), with a mean increase of 3.25 (95% confidence interval [CI] -5.38 to 11.88) three months later and a mean decrease of -1.82 (95% CI -16.01 to 12.38) after one year. The median utility at baseline was 0.76 (IQR 0.69 to 0.80), with a mean increase of 0.06 (95% CI -0.01 to 0.14) at three months and no change, 0.00 (-0.16 to 0.16), after one year. Conclusion Patients experienced a small but not statistically significant increase in QoL and utility three months after seeing a gastroenterologist for IBS, which was not maintained. Gastroenterology referral does not appear to appreciably improve Qol for most people with IBS.
引用
收藏
页数:13
相关论文
共 35 条
[1]   Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting [J].
Akehurst, RL ;
Brazier, JE ;
Mathers, N ;
O'Keefe, C ;
Kaltenthaler, E ;
Morgan, A ;
Platts, M ;
Walters, SJ .
PHARMACOECONOMICS, 2002, 20 (07) :455-462
[2]   A Positive Diagnostic Strategy Is Noninferior to a Strategy of Exclusion for Patients With Irritable Bowel Syndrome [J].
Begtrup, Luise M. ;
Engsbro, Anne Line ;
Kjeldsen, Jens ;
Larsen, Pia V. ;
de Muckadell, Ove Schaffalitzky ;
Bytzer, Peter ;
Jarbol, Dorte E. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) :956-+
[3]   Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome:: An analysis of the TENOR study [J].
Bracco, Andrea ;
Jonsson, Bengt ;
Ricci, Jean-Francois ;
Drummond, Michael ;
Nyhlin, Henry .
VALUE IN HEALTH, 2007, 10 (04) :238-246
[4]   Performance of the EQ-5D in patients with irritable bowel syndrome [J].
Bushnell, DM ;
Martin, ML ;
Ricci, JF ;
Bracco, A .
VALUE IN HEALTH, 2006, 9 (02) :90-97
[5]   Validation of electronic data capture of the irritable bowel syndrome - Quality of life measure, the work productivity and activity impairment questionnaire for irritable bowel syndrome and the EuroQol [J].
Bushnell, DM ;
Reilly, MC ;
Galani, C ;
Martin, ML ;
Ricci, JF ;
Patrick, DL ;
McBurney, CR .
VALUE IN HEALTH, 2006, 9 (02) :98-105
[6]   The epidemiology of irritable bowel syndrome [J].
Canavan, Caroline ;
West, Joe ;
Card, Timothy .
CLINICAL EPIDEMIOLOGY, 2014, 6 :71-80
[7]  
Cash B, 2005, AM J MANAG CARE, V11, pS4
[8]   The Yield of Colonoscopy in Patients With Non-Constipated Irritable Bowel Syndrome: Results From a Prospective, Controlled US Trial [J].
Chey, William D. ;
Nojkov, Borko ;
Rubenstein, Joel H. ;
Dobhan, Richard R. ;
Greenson, Joel K. ;
Cash, Brooks D. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (04) :859-865
[9]  
Dean BB, 2005, AM J MANAG CARE, V11, pS17
[10]   Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study [J].
Dove, Leonard S. ;
Lembo, Anthony ;
Randall, Charles W. ;
Fogel, Ronald ;
Andrae, David ;
Davenport, J. Michael ;
McIntyre, Gail ;
Almenoff, June S. ;
Covington, Paul S. .
GASTROENTEROLOGY, 2013, 145 (02) :329-+